Vascular effects and antihypertensive properties of κ-casein macropeptide

被引:42
作者
Miguel, Marta
Manso, Maria A.
Lopez-Fandino, Rosina
Alonso, Maria J.
Salaices, Mercedes
机构
[1] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, E-28029 Madrid, Spain
[2] CSIC, Inst Fermentac Ind, E-28006 Madrid, Spain
[3] Univ Rey Juan Carlos, Fac Ciencias Salud, Dept Ciencias Salud III, Madrid, Spain
关键词
kappa-casein macropeptide; vascular effects; antihypertensive properties; bioactive peptides;
D O I
10.1016/j.idairyj.2007.04.009
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The blood-pressure-lowering effect of bovine K-casein macropeptide (CMP), previously reported to exhibit a modest angiotensin-converting enzyme (ACE)-inhibitory activity in vitro, was evaluated in spontaneously hypertensive rats (SHR). The oral administration of CMP (150 mg kg(-1)) significantly reduced the systolic blood pressure (SBP) of SHR. The anti hypertensive action was more pronounced when CMP was treated with trypsin. The sequence MAIPPKK, identified in the tryptic hydrolysate of bovine CMP, significantly reduced blood pressure at a dose of 10mgkg(-1). The CMP and its tryptic peptides induced relaxation of endothelium-intact aortic rings. The sequence MAIPPKK also evoked a significant relaxation effect; however, the shorter sequence MAIPPK and the strong ACE-inhibitory tripeptide IPP exhibited a vascular relaxing effect lower than 10%. The implications of vascular relaxing mechanisms, as well as the possibility that the tripeptide IPP is at least partially responsible for the antihypertensive effects of CMP, are discussed. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1473 / 1477
页数:5
相关论文
共 31 条
[1]  
ATHERTON E, 1989, SOLID PHASE PEPTIDE, P131
[2]  
Brody EP, 2000, BRIT J NUTR, V84, pS39, DOI 10.1017/S0007114500002233
[3]   VALIDATION IN AWAKE RATS OF A TAIL-CUFF METHOD FOR MEASURING SYSTOLIC PRESSURE [J].
BUNAG, RD .
JOURNAL OF APPLIED PHYSIOLOGY, 1973, 34 (02) :279-282
[4]   CHARACTERIZATION OF AN ANTITHROMBOTIC PEPTIDE FROM KAPPA-CASEIN IN NEWBORN PLASMA AFTER MILK INGESTION [J].
CHABANCE, B ;
JOLLES, P ;
IZQUIERDO, C ;
MAZOYER, E ;
FRANCOUAL, C ;
DROUET, L ;
FIAT, AM .
BRITISH JOURNAL OF NUTRITION, 1995, 73 (04) :583-590
[5]   Casein peptide release and passage to the blood in humans during digestion of milk or yogurt [J].
Chabance, B ;
Marteau, P ;
Rambaud, JC ;
Migliore-Samour, D ;
Boynard, M ;
Perrotin, P ;
Guillet, R ;
Jollès, P ;
Fiat, AM .
BIOCHIMIE, 1998, 80 (02) :155-165
[6]   Influence of glycosylation on micelle-stabilizing ability and biological properties of C-terminal fragments of cow's kappa-casein [J].
Dziuba, J ;
Minkiewicz, P .
INTERNATIONAL DAIRY JOURNAL, 1996, 6 (11-12) :1017-1044
[7]   Characteristics and potential uses of the casein macropeptide [J].
ElSalam, MHA ;
ElShibiny, S ;
Buchheim, W .
INTERNATIONAL DAIRY JOURNAL, 1996, 6 (04) :327-341
[8]   Hypotensive peptides from milk proteins [J].
FitzGerald, RJ ;
Murray, BA ;
Walsh, DJ .
JOURNAL OF NUTRITION, 2004, 134 (04) :980S-988S
[9]   Peptide fragments released from Phe-caseinomacropeptide in vivo in the rat [J].
Fosset, S ;
Fromentin, G ;
Gietzen, DW ;
Dubarry, M ;
Huneau, JF ;
Antoine, JM ;
Lang, V ;
Mathieu-Casseron, F ;
Tomé, D .
PEPTIDES, 2002, 23 (10) :1773-1781
[10]   Characterization of new milk-derived inhibitors of angiotensin converting enzyme in vitro and in vivo [J].
Fuglsang, A ;
Nilsson, D ;
Nyborg, NCB .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2003, 18 (05) :407-412